HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Earnings Estimates Revisions
They're the most powerful force driving stock prices, and the key to the Zacks Rank's market-beating track record. Click here to learn more.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


BLUD: Immucor Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

IMMUCOR INC (NASD)
BLUD 18.44 0.01 (0.05%) Vol.  329,853 16:00 ET

Day Low - High 18.16 - 18.64
52wk Low - High 11.24 - 29.20
Avg Volume 633,630
Industry MED/DENTAL-SUPP
Market Cap 1.29 B
Div - Yield 0.00 - 0.00
PE (forward) 15.97
PEG Ratio 1.02
Current Year Est. 1.15
EPS Last Year 1.10
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 10/06/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
IMMUCOR INC BLUD PREMIUM
STERIS CORP STE PREMIUM
INVACARE CORP IVC PREMIUM
NOBEL BIOCARE NBHGF PREMIUM
See all MED/DENTAL-SUPP Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.33
ABR (Last Week) 2.33
# of Recs in ABR 9
Average Target Price 19.63
Industry Rank by ABR 72 out of 217
Rank in Industry 25 out of 36
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate BLUD?
Buy
Sell
Find out what the Zacks Community
thinks of BLUD at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR BLUD
Zacks Equity Research: Report for BLUD
Oct 06, 2009
Zacks Blog: Immucor Beats Estimates
Oct 05, 2009
Zacks Blog: Zacks Analyst Blog Highlights: Ingersoll-Rand plc, Caterpillar Inc., Dover Corporation, Immucor and Equinix Inc.
Jul 27, 2009
Zacks Blog: Immucor: Record Revenues
Jul 24, 2009
Zacks Blog: Immucor Replies to FDA Notice
Jul 15, 2009
More Zacks Commentary
NEWS
Immucor Up 12% Since SmarTrend's Buy Recommendation
Nov 05, 2009
Immucor (BLUD) Bullish Technical Alert - Trend Up 11.4%
Oct 27, 2009
Immucor Up 13.6% Since SmarTrend's Buy Recommendation
Oct 09, 2009
The Pomerantz Firm Charges Immucor, Inc. With Securities Fraud -- BLUD
Oct 02, 2009
Immucor Inc. Conference Call Today, 8:30 A.M.
Oct 02, 2009
More News
EARNINGS ESTIMATES
  This Quarter
11/2009
Next Quarter
02/2010
This Year
05/2010
Next Year
05/2011
Average Estimate 0.26 0.29 1.16 1.27
Number of Estimates 8 8 8 8
Low Estimates 0.22 0.25 1.09 1.19
High Estimate 0.27 0.30 1.19 1.34
Year Ago EPS 0.24 0.27 1.09 1.16
EPS Growth 6.77% 6.02% 5.96% 10.39%

More Estimates

COMPANY DESCRIPTION
Immucor is an international in vitro diagnostic company dedicated to automating manual processes in the hospital/donor laboratory. They develop, manufacture, and sell products used by hospital blood banks, clinical laboratories, and large blood-donor centers to test, detect, and identify certain properties of human blood prior to patient transfusion. Immucor's instruments utilize patented solid phase technology reagents to perform ABO grouping tests, RH typing, antibody screening, and platelet cross-matching.

Full Company Report
FINANCIALS
EPS TTM 1.1
Sales 300.55
Net Income 77.56
Price/Earnings 16.76
Price/Book 3.23
Price/Cash Flow 14.29
Price/Sales 4.17


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research